Autor: "ZHANG, D. Z." - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study.
Autorzy:: Li SY; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Li H; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Xiong YL; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Liu F; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Peng ML; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Zhang DZ; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Ren H; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Hu P; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.; Pokaż więcej
Źródło:: Journal of viral hepatitis [J Viral Hepat] 2017 Nov; Vol. 24 Suppl 1, pp. 12-20.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Hepatitis B virus*/immunology
Guanine/*analogs & derivatives
Hepatitis B e Antigens/*blood
Hepatitis B, Chronic/*blood
Hepatitis B, Chronic/*drug therapy
Interferon-alpha/*therapeutic use
Adult ; Biomarkers ; Cohort Studies ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/etiology ; Female ; Guanine/administration & dosage ; Guanine/adverse effects ; Guanine/therapeutic use ; Hepatitis B e Antigens/immunology ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/immunology ; Humans ; Incidence ; Interferon-alpha/administration & dosage ; Interferon-alpha/adverse effects ; Male ; Time Factors ; Treatment Outcome ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144.
Autorzy:: Xu JH; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Wang S; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Xu ZN; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd, Nanjing, China.
Yu YY; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Si CW; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Zeng Z; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Li J; Department of Infectious Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Mao Q; Department of Infectious Diseases, Southwest China Hospital, Chongqing, China.
Zhang DZ; Department of Infectious Diseases, The Second Affiliated Hospital with Chongqing Medical University, Chongqing, China.
Tang H; Department of Infectious Diseases, West China Hospital, Chengdu, China.
Sheng JF; Department of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Chen XY; Department of International Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Ning Q; Department and Institute of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Shi GF; Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Xie Q; Department of Infectious Diseases, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China.
Zhang XQ; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd, Nanjing, China.
Dai J; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd, Nanjing, China.; Pokaż więcej
Źródło:: Journal of viral hepatitis [J Viral Hepat] 2017 Oct; Vol. 24 (10), pp. 877-884. Date of Electronic Publication: 2017 Aug 11.
Typ publikacji:: Journal Article
MeSH Terms:: Genotype*
Maleates*/chemistry
Antiviral Agents/*therapeutic use
Guanine/*analogs & derivatives
Hepatitis B virus/*genetics
Hepatitis B, Chronic/*drug therapy
Hepatitis B, Chronic/*virology
Adult ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Antiviral Agents/chemistry ; Biomarkers ; DNA, Viral ; Drug Compounding ; Drug Resistance, Viral ; Female ; Guanine/administration & dosage ; Guanine/adverse effects ; Guanine/chemistry ; Guanine/therapeutic use ; Hepatitis B, Chronic/diagnosis ; Humans ; Male ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Viral Load ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir.
Autorzy:: Xu JH; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Song LW; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.; Xiamen Innovax Biotech Co., Ltd., Xiamen, China.
Li N; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Wang S; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Zeng Z; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Si CW; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Li J; Department of Infectious Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Mao Q; Department of Infectious Diseases, Southwest China Hospital, Chongqing, China.
Zhang DZ; Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Tang H; Department of Infectious Diseases, West China Hospital, Chengdu, China.
Sheng JF; State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Chen XY; Department of International Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Ning Q; Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Shi GF; Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Xie Q; Department of Infectious Diseases, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China.
Yuan Q; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
Yu YY; Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China.
Xia NS; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.; Pokaż więcej
Źródło:: Journal of viral hepatitis [J Viral Hepat] 2017 Feb; Vol. 24 (2), pp. 148-154. Date of Electronic Publication: 2016 Nov 28.
Typ publikacji:: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Antiviral Agents/*therapeutic use
Guanine/*analogs & derivatives
Hepatitis B Antibodies/*blood
Hepatitis B e Antigens/*blood
Hepatitis B, Chronic/*drug therapy
Hepatitis B, Chronic/*immunology
Adult ; China ; Female ; Guanine/therapeutic use ; Humans ; Male ; Prognosis ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities.
Autorzy:: Shao JY; Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Yin WW; Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Zhang QF; Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Liu Q; Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Peng ML; Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Hu HD; Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Hu P; Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Ren H; Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Zhang DZ; Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.; Pokaż więcej
Źródło:: Scandinavian journal of immunology [Scand J Immunol] 2016 Sep; Vol. 84 (3), pp. 182-90.
Typ publikacji:: Journal Article
MeSH Terms:: Immunity, Cellular*
Antigens, Differentiation, Myelomonocytic/*immunology
Killer Cells, Natural/*immunology
Lectins/*immunology
ADP-ribosyl Cyclase 1/genetics ; ADP-ribosyl Cyclase 1/immunology ; Antigens, Differentiation, Myelomonocytic/genetics ; Antigens, Differentiation, T-Lymphocyte/genetics ; Antigens, Differentiation, T-Lymphocyte/immunology ; Cell Degranulation ; Cell Lineage ; GPI-Linked Proteins/genetics ; GPI-Linked Proteins/immunology ; Gene Expression Regulation ; Humans ; Immunophenotyping ; Interferon-gamma/genetics ; Interferon-gamma/immunology ; Killer Cells, Natural/cytology ; Lectins/genetics ; Lysosomal-Associated Membrane Protein 1/genetics ; Lysosomal-Associated Membrane Protein 1/immunology ; Membrane Glycoproteins/genetics ; Membrane Glycoproteins/immunology ; NK Cell Lectin-Like Receptor Subfamily C/genetics ; NK Cell Lectin-Like Receptor Subfamily C/immunology ; Natural Cytotoxicity Triggering Receptor 1/genetics ; Natural Cytotoxicity Triggering Receptor 1/immunology ; Natural Cytotoxicity Triggering Receptor 3/genetics ; Natural Cytotoxicity Triggering Receptor 3/immunology ; Receptors, IgG/genetics ; Receptors, IgG/immunology ; Receptors, KIR2DL3/genetics ; Receptors, KIR2DL3/immunology ; Signal Transduction